Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

170 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Stage III non-small cell lung cancer (NSCLC) patients constitute a significant proportion of the lung cancer population. The prognosis of these patients has improved over the years due the introduction of combined modality treatment, including high-dose chemo-radiotherapy. The brain, however, remains one of the major sites of failure. Patients with brain metastasis suffer from a variety of neurological, cognitive and emotional difficulties that are known to adversely affect the health-related quality of life. Prophylactic Cranial Irradiation (PCI) can prevent or delay the development of brain metastasis, and as such can improve neurological disease-free survival and consequently health-related quality of life. But survival is short, and toxicities are real, as PCI in itself can also induce adverse effects. The cognitive adverse effects of PCI are not sufficiently illuminated and documented, due to the lack of formal and systematic evaluation in patient populations expected to have short survival. Also, recent attempts to reduce cognitive side effects of PCI by the application of hippocampal-avoidance PCI in order to prevent memory deficits have not been fully evaluated yet.

Before PCI can be offered routinely to stage III NSCLC patients in daily practice, the costs and benefits of this therapy should be investigated properly, to allow for well-informed treatment choices.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)

NCT04790253

Limited Stage Small Cell Lung Cancer Extensive-stage Small-cell Lung Cancer

RECRUITING NA

Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy

NCT00745797

Brain Metastases

TERMINATED PHASE3

Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy

NCT04829708

Limited Stage Small Cell Lung Cancer

RECRUITING PHASE3

Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC)

NCT02906384

Small Cell Lung Cancer

UNKNOWN PHASE2

Cognition and Patients With Lung Cancer

NCT07160751

Localized, Operable Non-small Cell Lung Cancer

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NSCLC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prophylactic Cranial Irradiation

NSCLC patients treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?

No interventions assigned to this group

no Prophylactic Cranial Irradiation

NSCLC patients not treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* UICC stage III A or III B (without malignant pleural or pericardial effusion) non-small cell lung cancer
* Whole body PDG-PET scan before the start of therapy available: no distant metastasis.
* CT or preferably MRI of the brain before the start of radical therapy available; no brain metastasis.
* Platinum-based chemotherapy is mandatory.
* Radical local therapy: concurrent or sequential chemotherapy and radiotherapy with or without surgery.
* Radiotherapy dose without surgery to at least biological equivalent of 60 Gy.
* No prior cranial irradiation.sufficient proficiency in Dutch language
* sufficient proficiency in Dutch language
* MRI (and not CT scan) pre-PCI